FGAM
ARCT icon

Financial Gravity Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Financial Gravity Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$34 – 1431
2024
Q1 		$34 Buy
+1
New +$35 ﹤0.01% 1069
2023
Q4 		– Hold
0
– – – 1261

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Financial Gravity Asset Management's ARCT Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Arcturus Therapeutics (ARCT) in Q2 2024, closing a stake of 1 share — an estimated $34 sold.

Financial Gravity Asset Management first reported a position in ARCT in Q1 2024 and held it in 1 quarter. The position peaked at $34 in Q1 2024. 171 funds tracked by Wall St. Rank hold ARCT as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Arcturus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 1 Arcturus Therapeutics share in Q2 2024, an estimated $34.
  • Financial Gravity Asset Management first reported a position in Arcturus Therapeutics in Q1 2024 and held it in 1 quarter.
  • Financial Gravity Asset Management's Arcturus Therapeutics position peaked at $34 in Q1 2024.
  • 171 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.